oxytocin + tranexamic acid + methylergometrine

This combination regimen is a prophylactic strategy developed for the primary prevention of postpartum hemorrhage (PPH) in women undergoing intrapartum cesarean section. The regimen consists of three distinct pharmacological agents: oxytocin, tranexamic acid, and an ergot derivative (specifically methylergometrine maleate). Oxytocin and methylergometrine act as uterotonics, stimulating uterine contractions to reduce blood loss, while tranexamic acid serves as an antifibrinolytic to stabilize clot formation. Cairo University is investigating this triple-drug regimen in clinical trials to compare its efficacy and cost-effectiveness against carbetocin alone, particularly in high-risk populations where standard uterotonic therapy may be insufficient.

Other names

oxytocin + tranexamic acid + ergot derivativeoxytocin + tranexamic acid + methylergometrine maleateOxytocin, Tranexamic Acid, and Ergot Derivative combination